Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 ConferenceGlobeNewsWire • 05/06/25
Ardelyx Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 05/01/25
Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 ConferenceGlobeNewsWire • 04/24/25
Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical MeetingsGlobeNewsWire • 04/10/25
Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical MeetingsGlobeNewsWire • 03/31/25
Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate AwardGlobeNewsWire • 03/13/25
Ardelyx: Limited Pipeline, Rising Costs, And Uncertain Growth Ahead (Downgrade)Seeking Alpha • 02/24/25
Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 02/20/25
Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025GlobeNewsWire • 01/30/25
Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic PrioritiesGlobeNewsWire • 01/13/25